| abstract |
The process comprises the oxidation of a racemic derivative of pyridine corresponding to general formula II, the reduction of the ketone obtained, the stereospecific locking or blocking of the OH group of the selected enantiomer alcohol, the opening of the acetonide cyle, the cyclization of the compound obtained and, if necessary, deprotection of the phenoxy group. The enantiomers obtained, corresponding to formula I, are useful as a therapeutically active ingredient. |